News & Updates

Changes in MetS diagnosis affects psoriasis risk
Changes in MetS diagnosis affects psoriasis risk
28 Dec 2021

The risk of psoriasis is elevated in patients with continuous metabolic syndrome (MetS) and in those with newly developed MetS, a recent study has found. In contrast, such risk is absent in individuals with only a history of MetS.

Changes in MetS diagnosis affects psoriasis risk
28 Dec 2021
Ixekizumab effective for difficult-to-treat psoriatic arthritis
Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021 byAudrey Abella

The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.

Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021